This inventor holds 1 USPTO granted patent. Top assignees: Galenisearch, Laboratories, Japan Science and Technology Agency, National Institute for Materials Science. Active years: 2008.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 1 
1 out of 1,328 
1 out of 575 
Years Active: 2008
Title: Yoko Miyamoto: A Pioneer in Sustained-Release Hormone Delivery
Introduction
Yoko Miyamoto, an innovative inventor based in Isehara, Japan, has made significant contributions to the field of biomedical engineering. With a focus on sustained-release drug delivery systems, her work has the potential to transform therapeutic applications of human growth hormone.
Latest Patents
Miyamoto holds a patent for her invention titled "Sustained-release microparticle preparation of human growth hormone and process for producing thereof." This pioneering work presents a sustained-release microparticle formulation that combines key benefits such as biodegradability and effective sustained-release performance. Remarkably, her formulation allows for the sustained release of human growth hormone over three days or more, while minimizing the initial burst release. Her microparticle preparation is capable of containing human growth hormone at concentrations of 10% or more and can quantitatively adsorb and encapsulate this hormone at rates of up to 20%. Additionally, the microparticles exhibit excellent dispersion and needle penetration properties, making them an effective tool for therapeutic uses.
Career Highlights
Throughout her career, Yoko Miyamoto has worked with esteemed organizations to further her research and development efforts. Notable among these are Galenisearch Laboratories and the Japan Science and Technology Agency. Her inventive spirit and dedication to science have allowed her to contribute to meaningful advancements in drug delivery technologies.
Collaborations
Miyamoto has collaborated with prominent colleagues in her field, including Yasuaki Ogawa and Takao Fujii. These partnerships have not only enriched her research endeavors but have also facilitated the dissemination of innovative solutions within the healthcare industry.
Conclusion
Yoko Miyamoto stands out as a remarkable inventor in the biomedical sector, particularly for her groundbreaking work in sustained-release formulations of human growth hormone. Her patent reflects a significant stride towards enhancing therapeutic efficiency while ensuring patient safety and comfort. With her continued research and collaborations, Miyamoto is poised to make even greater contributions to the realm of medical innovations.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile